
    
      This is a multi-center, prospective observational study to observe the incidence of adverse
      events under actual clinical settings to test the safety of Nanoxel-M inj. administration in
      patients with breast cancer, non-small cell lung cancer, prostate cancer, ovarian cancer,
      head & neck cancer, gastric cancer or esophageal cancer.
    
  